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Abstract 
Objectives: Leber’s hereditary optic neuropathy (LHON) is a mitochondrial genetic disease characterized by a vari-
able and reduced penetrance. Individuals carrying a primary LHON-causing mitochondrial DNA (mtDNA) mutation 
may either remain asymptomatic lifelong, as unaffected carriers, or develop sudden central visual loss that rapidly 
aggravates over some weeks. Over the years several genetic/environmental triggers able to modulate the risk of 
developing LHON have been proposed. We provided data supporting a possible correlation between LHON pen-
etrance and the mtDNA copy number, a raw index of mitochondrial mass, whose increase could represent a com-
pensatory response that cells implement to alleviate the pathogenic effect of the primary LHON-causing mtDNA 
mutations.
Data description: We collected Italian and Spanish subjects harboring one of the three common LHON primary 
mutations, either in heteroplasmic or homoplasmic status. For each population we were able to discriminate between 
affected subjects presenting typical clinical tracts of LHON and LHON-causing mutation carriers showing no symp-
toms correlated with vision loss. Each subject has been characterized for the presence of a LHON primary mutation, 
for its status of homoplasmy or heteroplasmy, and for the mtDNA content per cell, expressed as relative mtDNA/
nDNA ratio respect to controls. Additional clinical information is present for all the Italian subjects.
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Objective
Leber’s hereditary optic neuropathy (LHON) is typically 
characterized by a rapid bilateral central vision loss owing 
to focal degeneration of the retinal ganglion cell layer 
and optic nerve [1, 2]. The presence of primary muta-
tions in mitochondrial DNA (mtDNA) is necessary, but 
not sufficient alone, to cause optic neuropathy, because 
disease penetrance can even vary within different fami-
lies harboring the same mutation [3, 4]. Thus, the idea 
that other environmental and/or genetic factors might 
affect the penetrance and the risk of developing LHON 
is being reinforced over the last years [5, 6]. Nonetheless, 
when the etiology of a disease involves mitochondrial 
mutations it is mandatory to consider that the mtDNA is 
a multi-copy genome whose cell quantity varies depend-
ing on tissue type and pathophysiology factors. Further-
more, adjustment of the mtDNA content can represent a 
protective strategy cells perform to compensate whatever 
detrimental effect a mtDNA mutation is causing, whose 
efficacy is experimentally proven [7–9]. For instance, 
mitochondrial proliferation is commonly seen in post-
mitotic tissues such as skeletal muscle in patients with 
mitochondrial disease [10]. The mtDNA copy number 
can be assessed in peripheral blood and is thought to 
reflect variations in mitochondrial energetic function and 
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biogenesis occurring in other tissues otherwise unacces-
sible for diagnostic tests [11].
The purpose of the data collected was to provide sup-
port to a possible correlation between the mtDNA lev-
els and LHON penetrance in a population harboring a 
primary LHON-causing mutation. As already reported 
in other studies [12–16], unaffected mutation carriers 
showed the highest amount of mtDNA, regardless of the 
heteroplasmic/homoplasmic status. Furthermore, we 
observed that the mtDNA copy number progressively 
shifted towards higher values from controls to carriers, 
with the affected showing an intermediate value. This 
could suggest that in both carriers and affected individu-
als there is an activation of the mitochondrial biogenesis, 
somehow hindered in affected subjects.
Data description
We collected 124 subjects with a primary LHON-causing 
mutation (i.e., m.11778G > A or m.3460G > A), of which 
51 Italians and 73 Spanish. Two different control groups 
were considered, specifically 90 unrelated Italian healthy 
subjects and 28 unrelated Spanish healthy subjects 
(Table 1—Data set 1–3) [17–19], the latter used only for 
the analysis of the homoplasmic Spanish population as 
this was analyzed in a different laboratory, even if follow-
ing the same general procedures.
On the basis of clinical features and genetic mitochon-
drial analysis, we identified 46 Italians subjects, belong-
ing to 20 families, carrying a LHON-causing mutation 
in homoplasmy (37  m.11778G > A, distributed between 
18 affected and 19 carriers, and 9 m.3460G > A, of which 
5 affected and 4 carriers) (Table 1—Data set 1) [17] and 
52 Spanish (27  m.11778G > A, distributed between 18 
affected and 9 carriers, and 25 m.3460G > A, of which 6 
affected and 19 carriers) (Table 1—Data set 2) [18].
We also identified 26 subjects (Spanish and Italians), 
belonging to 12 families, carrying a LHON-causing muta-
tion in heteroplasmy, distributed as follows (Table  1—
Data set 3) [19]: 9 subjects with the m.11778G > A 
mutation (1 affected and 8 carriers), and 17 subjects 
with the m.3460G > A mutation (4 affected and 13 car-
riers). The mutant allele frequency was variable, ranging 
from 30 to 95% and from 5 to 95% for m.11778G > A and 
m.3460G > A, respectively.
These subjects were already partially described in our 
previous papers [13–15].
Subjects were collected at three sites: Ophthalmology 
Clinic, Policlinico Bari Hospital, Italy; Hospital IRCCS 
‘Casa Sollievo della Sofferenza’, Italy; and the University 
of Zaragoza, Spain. Prior written and informed consent 
was obtained from each subject according to Institu-
tional Guidelines. Several examinations were performed: 
slit-lamp biomicroscopy, fundal and optic nerve head 
stereoscopy, fluorescein angiography, optical coher-
ence tomography, and visual field testing. Total genomic 
DNA was extracted using the “Wizard® Genomic DNA 
Purification Kit” (Promega) from peripheral blood of 
the patients and their relatives with suspicion of LHON 
and from healthy control subjects. The presence of 
LHON mutations (m.3460G > A, m.11778G > A and 
m.14484T > C) was detected by PCR-RFLP and, if pre-
sent, confirmed by direct sequencing (ABI prism 310, 
Applied Biosystems). Quantification of mtDNA copy 
number was performed by qPCR using the relative 
method [20]. Mitochondrial and nuclear DNA quantities 
were measured amplifying genomic regions of ND1 and 
B2M genes, respectively. mtDNA/nDNA ratio was calcu-
lated for each sample and this value was then calibrated 
relative to the geometric mean of controls (i.e., relative 
mtDNA/nDNA ratio). For further details see Data file 1 
(Table 1) [21].
Summing up the homoplasmic population data, in Ital-
ian subjects the mtDNA content (measured as relative 
mtDNA/nDNA ratio and expressed as geometric mean 
and confidence interval CI) was 100 (CI 93.38, 107.09) 
in controls, 133.72 (CI 112.34, 159.17) in affected and 
173.97 (CI 140.53, 215.37) in carriers; in Spanish popu-
lation we measured these mean values: controls 100 (CI 
83.79, 119.35, affected 104.29 (CI 86.02, 126.44), and car-
riers 147.73 (CI 124.82, 174.84).
Table 1 Overview of data sets
Label Name of data file/data set File types (file extension) Data repository and identifier (DOI or accession 
number)
Data set 1 Italian subjects with a LHON-causing mutation in 
homoplasmy [13, 17]
MS Excel file (.xlsx) Figshare (https ://doi.org/10.6084/m9.figsh are.70935 
59.v1)
Data set 2 Spanish subjects with a LHON-causing mutation in 
homoplasmy [15, 18]
MS Excel file (.xlsx) Figshare (https ://doi.org/10.6084/m9.figsh are.70936 
19.v1)
Data set 3 Italian and Spanish subjects with a LHON-causing 
mutation in heteroplasmy [14, 19]
MS Excel file (.xlsx) Figshare (https ://doi.org/10.6084/m9.figsh are.70936 
43.v1)
Data file 1 Methods [21] MS Word file (.docx) Figshare (https ://doi.org/10.6084/m9.figsh are.71338 
40.v3)
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Heteroplasmic subjects showed these relative 
mtDNA/nDNA ratio mean values: controls 100 (CI 
93.38, 107.09), affected 140.25 (CI 89.51, 219.75) and 
carriers 234.54 (CI 197.45, 278.61).
Limitations
These data do not consider other known variables, such 
as mtDNA haplotypes and nuclear genetic background 
that represents likely triggers of LHON and are known 
to influence penetrance and age of onset.
Abbreviations
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nDNA: nuclear DNA; CI: confidence interval.
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